“The existing problem has uncovered some structural weaknesses during the EU’s medicines source chain plus a superior dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides reported. She encouraged that offer chain concerns be dealt with in an EU pharmaceutic